Astrazeneca plc

NASDAQ: AZN
$68.55
+$0.19 (+0.3%)
Closing price April 19, 2024
AstraZeneca is a global biopharmaceutical giant, dedicated to the discovery, development, and commercialization of prescription medicines. Its portfolio spans a wide range of areas including cardiovascular, renal, metabolism, oncology, and treatments for rare diseases and COVID-19. The company is known for leading products like Tagrisso, Imfinzi, and Lynparza, among others. AstraZeneca not only serves healthcare professionals and patients worldwide but also engages in significant collaborations, such as with Neurimmune AG, to push the boundaries of medicine. Headquartered in Cambridge, UK, AstraZeneca continues to be at the forefront of addressing global health challenges.
With the pandemic largely in the rear-view mirror, COVID-19 vaccine winner Novavax has seen shares fall. Yet, analysts have high hopes for the stock.
Here is an assessment of how safe the dividend at AbbVie appears to be based on a variety of metrics, including its status as a Dividend Aristocrat.
Analysts have been cutting ratings and price targets recently, but here are four stocks that defying the downward pressure.
This year’s Artificial Intelligence rally led by the so-called “Magnificent 7” has been fantastic if you owned those stocks. The reality is the great bulk of the S&P 500 is treading water for...
The federal CHIPS Act signed into law by President Joe Biden in August 2022 is offering $52 billion in federal subsidies to boost America’s semiconductor industry. The goal is to reduce U.S....
Tuesday's top analyst upgrades and downgrades included AstraZeneca, Ballard Power Systems, Bloom Energy, BHP, Cleveland-Cliffs, CrowdStrike, Dow, Nike, Plains All-American Pipeline, Sealed Air and...
Friday's top analyst upgrades and downgrades included Ally Financial, American Express, AppLovin, AstraZeneca, Coinbase Global, Cognizant Technology Solutions, Comcast, CME, CrowdStrike, Delta Air...
Before U.S. markets open on Thursday, these three companies will be among those reporting quarterly earnings.
Wednesday's additional top analyst upgrades and downgrades were on AstraZeneca, Bilibili, Electronic Arts, GoodRx, NetEase, Netflix, Pinterest, U.S. Foods and more.
Monday’s top analyst upgrades and downgrades included Affirm, AstraZeneca, Broadcom, Centene, Dell Technologies, Dollar General, Marvell Technology, Medical Properties Trust, Tesla, Ulta Beauty,...
Tuesday's additional top analyst upgrades and downgrades were on Adobe, AstraZeneca, Best Buy, Chemours, Oracle, Royalty Pharma, Teva Pharmaceutical and Tractor Supply.
Here are previews of three pharmaceutical giants set to report earnings before markets open on Friday.
Friday afternoon's top analyst upgrades and downgrades included Affirm, AstraZeneca, Block, CVS, Kellogg and more.
Tuesday afternoon's top analyst upgrades and downgrades included Alibaba, Apple, AstraZeneca, Canopy Growth, CNX Resources, Murphy Oil, Ross Stores and Tesla.
With the potential for far lower returns in the coming year, total return becomes a key ingredient for investment success. These five top health care stocks look like very solid ideas for 2022, as...